TY - JOUR
T1 - Molecular subtyping of male breast cancer by immunohistochemistry
AU - Kornegoor, Robert
AU - Verschuur-Maes, Anoek H J
AU - Buerger, Horst
AU - Hogenes, Marieke C H
AU - De Bruin, Peter C.
AU - Oudejans, Joost J.
AU - Van Der Groep, Petra
AU - Hinrichs, Bernd
AU - Van Diest, Paul J.
PY - 2012/3
Y1 - 2012/3
N2 - Molecular subtyping of breast cancer by gene expression has proven its significance in females. Immunohistochemical surrogates have been used for this classification, because gene expression profiling is not yet routinely feasible. Male breast cancer is rare and large series are lacking. In this study, we used immunohistochemistry for molecular subtyping of male breast cancer. A total of 134 cases of male breast cancer were immunohistochemically stained on tissue microarrays for estrogen receptor (ER), progesterone receptor (PR), HER2 and epidermal growth factor receptor (EGFR), as well as for CK5/6, CK14, and Ki67. HER2 was also assessed by chromogen in situ hybridization. Cases were classified as luminal A (ER+ and/or PR+, and HER2-and Ki67 low), luminal B (ER+ and/or PR+, and HER2+ or Ki67 high), HER2 driven (ER-, PR-, HER2+), basal-like (ER-, PR-, HER2-, CK5/6+ and/or CK14+ and/or EGFR), or unclassifiable triple-negative (negative for all six markers). Luminal type A was by far the most encountered type of male breast cancers, representing 75% of the cases. Luminal type B was seen in 21% and the remaining 4% of cases were classified as basal-like (n=4) and unclassifiable triple-negative (n=1). No HER2 driven cases were identified. Patients with basal-like cancer were significantly younger (P=0.034). Luminal B type cancers showed significantly higher histological grade (P
AB - Molecular subtyping of breast cancer by gene expression has proven its significance in females. Immunohistochemical surrogates have been used for this classification, because gene expression profiling is not yet routinely feasible. Male breast cancer is rare and large series are lacking. In this study, we used immunohistochemistry for molecular subtyping of male breast cancer. A total of 134 cases of male breast cancer were immunohistochemically stained on tissue microarrays for estrogen receptor (ER), progesterone receptor (PR), HER2 and epidermal growth factor receptor (EGFR), as well as for CK5/6, CK14, and Ki67. HER2 was also assessed by chromogen in situ hybridization. Cases were classified as luminal A (ER+ and/or PR+, and HER2-and Ki67 low), luminal B (ER+ and/or PR+, and HER2+ or Ki67 high), HER2 driven (ER-, PR-, HER2+), basal-like (ER-, PR-, HER2-, CK5/6+ and/or CK14+ and/or EGFR), or unclassifiable triple-negative (negative for all six markers). Luminal type A was by far the most encountered type of male breast cancers, representing 75% of the cases. Luminal type B was seen in 21% and the remaining 4% of cases were classified as basal-like (n=4) and unclassifiable triple-negative (n=1). No HER2 driven cases were identified. Patients with basal-like cancer were significantly younger (P=0.034). Luminal B type cancers showed significantly higher histological grade (P
KW - breast cancer
KW - immunohistochemistry
KW - male
KW - molecular typing
UR - http://www.scopus.com/inward/record.url?scp=84857791638&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84857791638&partnerID=8YFLogxK
U2 - 10.1038/modpathol.2011.174
DO - 10.1038/modpathol.2011.174
M3 - Article
C2 - 22056953
AN - SCOPUS:84857791638
SN - 0893-3952
VL - 25
SP - 398
EP - 404
JO - Modern Pathology
JF - Modern Pathology
IS - 3
ER -